TQB2934 injection for light chain amyloidosis
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with systemic light chain (AL) amyloidosis and it has come back or worsened after at least one previous treatment.
- Your heart-related blood test (NT-proBNP) level is 8,500 ng/L or lower.
- You are willing to use effective contraception if you or your partner could become pregnant.
- You have not had certain other types of amyloidosis, active multiple myeloma, or certain other blood cancers.
- You have not had major surgery or certain other treatments within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called TQB2825, given as a shot under the skin, for people with certain types of blood cancer (B-cell lymphomas) that have come back or stopped responding to previous CD20 antibody treatments. The goal is to see if it is safe and works.
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
This trial tests a new drug called TQB2825 against standard immunotherapy for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if TQB2825 works better at controlling the lymphoma.
Hear when a new Systemic Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.